• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Virol J . Phillyrin ameliorates influenza a virus-induced pulmonary inflammation by antagonizing CXCR2 and inhibiting NLRP3 inflammasome activation

tetano

Editor, Senior Moderator
Virol J


. 2023 Nov 13;20(1):262.
doi: 10.1186/s12985-023-02219-4. Phillyrin ameliorates influenza a virus-induced pulmonary inflammation by antagonizing CXCR2 and inhibiting NLRP3 inflammasome activation

Shanyu Zhang[SUP] #[/SUP][SUP] 1 2 3 [/SUP], Fengzhi Sun[SUP] #[/SUP][SUP] 4 [/SUP], Jinlu Zhu[SUP] 1 [/SUP], Jianhong Qi[SUP] 5 [/SUP], Wenjing Wang[SUP] 1 [/SUP], Ziming Liu[SUP] 1 [/SUP], Wenqian Li[SUP] 1 [/SUP], Chuanguo Liu[SUP] 1 6 3 [/SUP], Xuehuan Liu[SUP] 1 6 [/SUP], Nonghan Wang[SUP] 1 [/SUP], Xinyu Song[SUP] 1 [/SUP], Dan Zhang[SUP] 7 8 9 10 [/SUP], Dongmei Qi[SUP] 11 12 13 14 [/SUP], Xiaolong Wang[SUP] 15 16 17 18 [/SUP]



Affiliations
Abstract

Influenza is an acute viral respiratory illness with high morbidity rates worldwide. Excessive pulmonary inflammation is the main characteristic of lethal influenza A virus (IAV) infections. Therapeutic options for managing influenza are limited to vaccines and some antiviral medications. Phillyrin is one of the major bioactive components of the Chinese herbal medicine Forsythia suspensa, which has the functions of sterilization, heat clearing and detoxification. In this work, the effect and mechanism of phillyrin on H1N1 influenza (PR8)-induced pneumonia were investigated. We reported that phillyrin (15 mg/kg) treatment after viral challenge significantly improved the weight loss, ameliorated pulmonary inflammation and inhibited the accumulation of multiple cytokines and chemokines in bronchoalveolar lavage fluid on 7 days post infection (dpi). In vitro, phillyrin suppressed influenza viral replication (Matrixprotein and nucleoprotein messenger RNA level) and reduced influenza virus-induced cytopathic effect (CPE). Furthermore,chemokine receptor CXCR2 was confirmed to be markedly inhibited by phillyrin. Surface plasmon resonance results reveal that phillyrin exhibits binding affinity to CXCR2, having a binding affinity constant (KD) value of 1.858e-5 M, suggesting that CXCR2 is a potential therapeutic target for phillyrin. Moreover, phillyrin inhibited the mRNA and protein expression levels of Caspase1, ASC and NLRP3 in the lungs of mice with H1N1-induced pneumonia.This study reveals that phillyrin ameliorates IAV-induced pulmonary inflammation by antagonizing CXCR2 and inhibiting NLRP3 inflammasome activation partly.

Keywords: CXCR2; Influenza; NLRP3; Phillyrin; Pulmonary inflammation.

 
Back
Top Bottom